<?xml version='1.0' encoding='UTF-8'?>
<search_results><query id="7103">cystic fibrosis treatment</query><engine status="OK" timestamp="2014-04-21 08:59:59" name="SpringerLink" id="FW14-e013"/><snippets><snippet id="FW14-e013-7103-01"><link cache="FW14-topics-docs/e013/7103_01.html" timestamp="2014-04-21 09:00:00">http://link.springer.com/article/10.2165/00128413-199208360-00019</link><title>Genentech’s novel cystic fibrosis treatment</title><description>Inpharma Weekly (1992)</description></snippet><snippet id="FW14-e013-7103-02"><link cache="FW14-topics-docs/e013/7103_02.html" timestamp="2014-04-21 09:02:53">http://link.springer.com/article/10.2165/00128413-199208300-00018</link><title>No adverse effects with Genentech’s novel cystic fibrosis treatment</title><description>Inpharma Weekly (1992)</description></snippet><snippet id="FW14-e013-7103-03"><link cache="FW14-topics-docs/e013/7103_03.html" timestamp="2014-04-21 09:04:07">http://link.springer.com/article/10.1023/A%3A1026349303930</link><title>Maternal Attributions Related to Compliance with Cystic Fibrosis Treatment</title><description>Steven A. Hobbs, Julie B. Schweitzer… in Journal of Clinical Psychology in Medical … (2003)</description></snippet><snippet id="FW14-e013-7103-04"><link cache="FW14-topics-docs/e013/7103_04.html" timestamp="2014-04-21 09:07:37">http://link.springer.com/article/10.1007/BF03311041</link><title>Oral Treatment for Chronic P.aeruginosa Infections in Cystic Fibrosis?</title><description>InPharma (1987)</description></snippet><snippet id="FW14-e013-7103-05"><link cache="FW14-topics-docs/e013/7103_05.html" timestamp="2014-04-21 09:09:05">http://link.springer.com/article/10.1007/BF03317272</link><title>TREATMENT OF CHILDREN WITH CYSTIC FIBROSIS</title><description>InPharma (1980)</description></snippet><snippet id="FW14-e013-7103-06"><link cache="FW14-topics-docs/e013/7103_06.html" timestamp="2014-04-21 09:10:33">http://link.springer.com/article/10.2165/00128413-200213580-00027</link><title>Azithromycin beneficial in treatment-refractory cystic fibrosis</title><description>Inpharma Weekly (2002)</description></snippet><snippet id="FW14-e013-7103-07"><link cache="FW14-topics-docs/e013/7103_07.html" timestamp="2014-04-21 09:11:40">http://link.springer.com/article/10.1007/BF03277274</link><title>Outpatient antibacterial treatment cost saving in cystic fibrosis</title><description>PharmacoEconomics &amp; Outcomes News Weekly (1998)</description></snippet><snippet id="FW14-e013-7103-08"><link cache="FW14-topics-docs/e013/7103_08.html" timestamp="2014-04-21 09:13:41">http://link.springer.com/article/10.2165/00128413-200313760-00004</link><title>Advances in the treatment of cystic fibrosis</title><description>Inpharma Weekly (2003)</description></snippet><snippet id="FW14-e013-7103-09"><link cache="FW14-topics-docs/e013/7103_09.html" timestamp="2014-04-21 09:15:05">http://link.springer.com/article/10.1007/BF03303322</link><title>AZLOCILLIN ALONE FOR THE TREATMENT OF CYSTIC FIBROSIS?</title><description>InPharma (1983)</description></snippet><snippet id="FW14-e013-7103-10"><link cache="FW14-topics-docs/e013/7103_10.html" timestamp="2014-04-21 09:17:21">http://link.springer.com/article/10.1007/BF02014882</link><title>Fosfomycin in the treatment of cystic fibrosis</title><description>D. Katznelson, Y. Yahav, E. Rubinstein in European Journal of Clinical Microbiology (1984)</description></snippet></snippets></search_results>